COMMUNIQUÉS West-GlobeNewswire

60 Degrees Pharma Announces $1.075 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
05/02/2025
WASHINGTON, Feb. 05, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (the “Company”), a pharmaceutical company focused on developing new medicines for infectious diseases, today announced [...]
FibroBiologics to Host In-Person Analyst Day to Provide Research & Development Updates
05/02/2025
FibroBiologics to also present at the BIO CEO & Investor Conference HOUSTON, Feb. 05, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics”), a clinical-stage biotechnology company with 160 [...]
Nuvectis Pharma Announces Pricing of $13.5 Million Public Offering of Common Stock
05/02/2025
FORT LEE, N.J., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (Nasdaq: NVCT), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of [...]
New Survey from Aeroflow Urology Reveals Lack of Postpartum Incontinence Care Causes Lasting Health Problems for Mothers
05/02/2025
Despite 85% of mothers experiencing frequent bladder leaks during postpartum, the survey found only 15% of mothers received resources and supplies from their providers to help manage their incontinence ASHEVILLE, N.C., [...]
Annovis Bio, Inc. Announces Closing of $21 Million Public Offering
04/02/2025
MALVERN, PA, Feb. 04, 2025 (GLOBE NEWSWIRE) -- via IBN - Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative [...]
Jasper Therapeutics to Present at the Oppenheimer Healthcare Life Sciences Conference
04/02/2025
REDWOOD CITY, Calif., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting [...]
Monthly information on share capital and company voting rights
04/02/2025
(Article 223-16 of General Regulation of the French financial markets authority) PARIS, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 Date Total number of shares in the [...]
Conavi Medical Retains BND Projects Inc. for Corporate Development Services
04/02/2025
TORONTO, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Conavi Medical Corp. (TSXV: CNVI) (“ Conavi ” or the “ Corporation ”), a commercial stage medical device company focused on designing, manufacturing, and marketing imaging [...]
Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
04/02/2025
(Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers) PARIS, 04 févr. 2025 (GLOBE NEWSWIRE) -- Place de cotation : Euronext Growth ISIN code: FR0010425595 Date Nombre total d’actions composant le [...]
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04/02/2025
SAN FRANCISCO, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and [...]
CVRx Reports Fourth Quarter and Full Year 2024 Financial and Operating Results
04/02/2025
MINNEAPOLIS, Feb. 04, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients [...]
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04/02/2025
WALTHAM, Mass., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals , Inc. (Nasdaq: APLS) announced today that the company approved the grant of equity awards to three new employees with a grant date of February 3 [...]
InnovAge Announces Financial Results For the Fiscal Second Quarter Ended December 31, 2024
04/02/2025
DENVER, Feb. 04, 2025 (GLOBE NEWSWIRE) -- InnovAge Holding Corp. (“InnovAge” or the “Company”) (Nasdaq: INNV), an industry leader in providing comprehensive healthcare programs to frail, predominantly dual-eligible [...]
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04/02/2025
CAMBRIDGE, Mass., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted seven newly [...]
Exagen Inc. to Participate in Upcoming Investor Conferences
04/02/2025
CARLSBAD, Calif., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, today announced that management will participate in the following upcoming investor conferences: [...]
Nuvectis Pharma Announces Proposed Public Offering of Common Stock
04/02/2025
FORT LEE, NJ, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (Nasdaq: NVCT), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious [...]
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
04/02/2025
SAN DIEGO, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)- [...]
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
04/02/2025
CAMBRIDGE, Mass., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today [...]
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04/02/2025
SOUTH SAN FRANCISCO, Calif., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on January 31, 2025 it granted stock options to purchase an aggregate of 64,587 shares of [...]

Pages